Contribution of allergen immunotherapy using Phostal in the treatment of seasonal allergic rhinitis (two years of use)
Authors:
L. Bartošíková 1; J. Nečas 1; T. Bartošík 2; M. Pavlík 2; J. Fráňová 3
Authors place of work:
Univerzita Palackého v Olomouci, Lékařská fakulta, Ústav fyziologie
1; Fakultní nemocnice U sv. Anny v Brně, Anesteziologicko-resuscitační klinika
2; Fakultní nemocnice Brno, Dětská nemocnice, II. dětská klinika
3
Published in the journal:
Čes. slov. Farm., 2008; 57, 99-102
Category:
Original Articles
Summary
Allergen immunotherapy consists in the administration of the appropriate allergen to which the patient is hypersensitive. The objective is to induce immunological tolerance of the organism. In the present study, the effect of the administration of Phostal on the occurrence of seasonal symptoms of pollinosis in a group of 35 outpatients was observed during two years. The substance was administered according to the regular dosage schedule, all year round. The results of the study have demonstrated a significant effect of the product on the decrease in the occurrence of observed objective symptoms of the disease, starting already from the first year of treatment. This is in correlation with changes in the spirometric functions, selected laboratory parameters and results of the prick tests in the treated group in comparison to the control group.
Key words:
allergen immunotherapy – pollinosis – Phostal
Zdroje
1. Noon, L.: Lancet, 1911; 1, 1572–1573.
2. Freeman, J.: Lancet, 1914; 1, 1178.
3. Rybníček, O., Seberová, E.: Průvodce alergenovou imunoterapií. 1. vyd. Praha, ČIPA, 2004.
4. Pereira, C., Botelho, F., Tavarez, B.: Allerg. Immunol., 2004; 36, 375–386.
5. Schmidt-Weber, C. B., Laser, K.: Curr. Opin. Aller. Clin. Immunol., 2005; 5, 525–530.
6. Akdis, C. A., Barlan, I. B., Bahceciler, N., Akdis, M.: Allergy, 2006; 61 (Suppl 81), 11–14.
7. Batard, T.: Alergie, 1999; 3, 12–14.
8. Bouquet, J., Jockey, H. J.: Allergy, 1998; 53 (Suppl. 44), 4–42.
9. Bartošíková, L., Fráňa, L., Nečas, J., Fráňa, P.: Klin. Imunol. Alergol., 2000; 1, 5–10.
10. Santilli, J., Nathan, R.: Ann. Allergy Asthma Immunol., 2001; 86, 219–225.
11. Miller, C., Dreborg, S., Ferdousi, H. A. et al.: J. Allergy Clin. Immunol., 2002; 109, 251–256.
12. Feliziani, V.: Allergol. Immunopathol., 1995; 23, 224–230.
13. Gonzales, P., Florido, F.: J. Invest. Allerg. Clin Immunol., 2002; 12, 263–271.
14. Vondra, V., Malý, M., Rybníček, O. et al.: Alergie, 2004; 1, www.tigis.cz.
15. Park, H. S., Hahm, D. H., Kim, H. Y. et al.: Ann. Allergy. Asthma Immunol., 2001; 86, 444–448.
16. Tonnel, A. B., Scherpereel, A.: Allergy, 2004; 59, 491–497.
17. Hansen, I., Normann, K.: Laryngo Rhin. Otol., 2003; 82, 558–563.
18. Polosa, R., Gotti M., Li, F., Mangano, G.: J. Brit. Soc. Allergy, 2003; 33, 873–881.
19. Wilson, D. R., Lima, L., Torres, M., Durham, S. R.: Allergy, 2005; 1, 4–12.
20. Ariano, R., Orion, A. M., Augeri, G. et al.: Allergy, 1999; 54(4), 313–319.
21. Di Rienzo, V., Marcucci, F., Puccinelli, P. et al.: Clin. Exp. Allergy, 2003; 33, 206–210.
Štítky
Pharmacy Clinical pharmacologyČlánok vyšiel v časopise
Czech and Slovak Pharmacy
2008 Číslo 2
Najčítanejšie v tomto čísle
- Semisynthetic cellulose derivatives as the base of hydrophilic gel systems
- Lactobacilli and their probiotic properties
- Standard prescriptions for the formulation of medicinal preparations in pharmacies I. Suspensions for dermal administration
- Medicinal plants and diabetes mellitus